Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference
Eledon Pharmaceuticals (Nasdaq: ELDN) will present at the Guggenheim Second Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 10:30 a.m. ET (7:30 a.m. PT).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eledon Pharmaceuticals (Nasdaq: ELDN) will present at the Guggenheim Second Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 10:30 a.m. ET (7:30 a.m. PT). David-Alexandre C. Gros, M.D., CEO, will deliver the presentation. A live webcast will be available with a replay posted on the company website under Events for registered users.
Details
News Market Reaction – ELDN
On Nov 5, the day this news came out, ELDN closed 3.12% below the previous close.
Data tracked by StockTitan Argus for the Nov 5 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will present at the upcoming Guggenheim Second Annual Healthcare Innovation Conference on Wednesday, November 12, 2025, at 10:30 a.m. ET (7:30 a.m. PT).
To register in advance for the webcast, sign up here.
A webcast replay will be accessible following the live session on the Company’s website under Events.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com
Source: Eledon Pharmaceuticals
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.